These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 7898771)
41. Comparative effects of selective kappa-opioid receptor agonists on dopamine levels in the dorsal caudate of freely moving rats. Zaratin P; Clarke GD Eur J Pharmacol; 1994 Oct; 264(2):151-6. PubMed ID: 7851477 [TBL] [Abstract][Full Text] [Related]
42. Mechanisms of Kappa Opioid Receptor Potentiation of Dopamine D2 Receptor Function in Quinpirole-Induced Locomotor Sensitization in Rats. Escobar AP; González MP; Meza RC; Noches V; Henny P; Gysling K; España RA; Fuentealba JA; Andrés ME Int J Neuropsychopharmacol; 2017 Aug; 20(8):660-669. PubMed ID: 28531297 [TBL] [Abstract][Full Text] [Related]
43. Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens. Ehrich JM; Phillips PE; Chavkin C Neuropsychopharmacology; 2014 Dec; 39(13):3036-48. PubMed ID: 24971603 [TBL] [Abstract][Full Text] [Related]
44. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Acri JB; Thompson AC; Shippenberg T Synapse; 2001 Mar; 39(4):343-50. PubMed ID: 11169785 [TBL] [Abstract][Full Text] [Related]
45. Opioid receptor-mediated inhibition of dopamine and acetylcholine release from slices of rat nucleus accumbens, olfactory tubercle and frontal cortex. Heijna MH; Padt M; Hogenboom F; Portoghese PS; Mulder AH; Schoffelmeer AN Eur J Pharmacol; 1990 Jun; 181(3):267-78. PubMed ID: 2166675 [TBL] [Abstract][Full Text] [Related]
46. Interactions between kappa opioid agonists and cocaine. Preclinical studies. Mello NK; Negus SS Ann N Y Acad Sci; 2000; 909():104-32. PubMed ID: 10911926 [TBL] [Abstract][Full Text] [Related]
47. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442 [TBL] [Abstract][Full Text] [Related]
48. Samidorphan, an opioid receptor antagonist, attenuates drug-induced increases in extracellular dopamine concentrations and drug self-administration in male Wistar rats. Cunningham JI; Todtenkopf MS; Dean RL; Azar MR; Koob GF; Deaver DR; Eyerman DJ Pharmacol Biochem Behav; 2021 May; 204():173157. PubMed ID: 33647274 [TBL] [Abstract][Full Text] [Related]
49. The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats. Jewett DC; Grace MK; Jones RM; Billington CJ; Portoghese PS; Levine AS Brain Res; 2001 Aug; 909(1-2):75-80. PubMed ID: 11478923 [TBL] [Abstract][Full Text] [Related]
50. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum. Capasso A; Sorrentino L Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209 [TBL] [Abstract][Full Text] [Related]
51. Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Donzanti BA; Althaus JS; Payson MM; Von Voigtlander PF Res Commun Chem Pathol Pharmacol; 1992 Nov; 78(2):193-210. PubMed ID: 1282270 [TBL] [Abstract][Full Text] [Related]
52. Kappa-opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administration. Doyon WM; Howard EC; Shippenberg TS; Gonzales RA Neuropharmacology; 2006 Sep; 51(3):487-96. PubMed ID: 16781738 [TBL] [Abstract][Full Text] [Related]
53. The kappa opioid agonist U50,488 potentiates 6-hydroxydopamine-induced neurotoxicity on dopaminergic neurons. Marin C; Bové J; Serrats J; Cortés R; Mengod G; Tolosa E Exp Neurol; 2005 Jan; 191(1):41-52. PubMed ID: 15589511 [TBL] [Abstract][Full Text] [Related]
54. Effects of kappa-opioid receptor agonists on long-term cocaine use and dopamine neurotransmission. Collins SL; D'Addario C; Izenwasser S Eur J Pharmacol; 2001 Aug; 426(1-2):25-34. PubMed ID: 11525767 [TBL] [Abstract][Full Text] [Related]
55. Orphanin FQ/nociceptin attenuates motor stimulation and changes in nucleus accumbens extracellular dopamine induced by cocaine in rats. Lutfy K; Do T; Maidment NT Psychopharmacology (Berl); 2001 Feb; 154(1):1-7. PubMed ID: 11291998 [TBL] [Abstract][Full Text] [Related]
56. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. Devine DP; Leone P; Pocock D; Wise RA J Pharmacol Exp Ther; 1993 Sep; 266(3):1236-46. PubMed ID: 7690399 [TBL] [Abstract][Full Text] [Related]
57. Induction of Fos-like immunoreactivity by opioids in guinea-pig brain. Bot G; Chahl LA Brain Res; 1996 Aug; 731(1-2):45-56. PubMed ID: 8883853 [TBL] [Abstract][Full Text] [Related]
58. Differential Roles of Accumbal GSK3 Shi X; Barr JL; von Weltin E; Wolsh C; Unterwald EM J Pharmacol Exp Ther; 2019 Nov; 371(2):339-347. PubMed ID: 31420527 [TBL] [Abstract][Full Text] [Related]
59. Central kappa opioid receptor-evoked changes in renal function in conscious rats: participation of renal nerves. Kapusta DR; Obih JC J Pharmacol Exp Ther; 1993 Oct; 267(1):197-204. PubMed ID: 8229746 [TBL] [Abstract][Full Text] [Related]
60. Blockade of delta-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Acquas E; Meloni M; Di Chiara G Eur J Pharmacol; 1993 Jan; 230(2):239-41. PubMed ID: 8380771 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]